Literature DB >> 22108937

Adenosine in cold blood cardioplegia--a placebo-controlled study.

Anders Ahlsson1, Claudio Sobrosa, Lennart Kaijser, Eva Jansson, Vollmer Bomfim.   

Abstract

OBJECTIVE Adenosine as an additive in blood cardioplegia is cardioprotective in animal studies, but its clinical role in myocardial protection remains controversial. The aim of this study was to investigate whether the addition of adenosine in continuous cold blood cardioplegia would enhance myocardial protection. METHODS In a prospective double-blind study comparing adenosine 400 μmol l(-1) to placebo in continuous cold blood cardioplegia, 80 patients undergoing isolated aortic valve replacement were randomized into four groups: antegrade cardioplegia with adenosine (n = 19), antegrade cardioplegia with placebo (n = 21), retrograde cardioplegia with adenosine (n = 21) and retrograde cardioplegia with placebo (n = 19). Myocardial arteriovenous differences in oxygen and lactate were measured before, during and after aortic occlusion. Myocardial concentrations of adenine nucleotides and lactate were determined from left ventricular biopsies obtained before aortic occlusion, after bolus cardioplegia, at 60 min of aortic occlusion and at 20 min after aortic occlusion. Plasma creatine kinase (CK-MB) and troponin T were measured at 1, 3, 6, 9, 12 and 24 h after aortic occlusion. Haemodynamic profiles were obtained before surgery and 1, 8 and 24 h after cardiopulmonary bypass. Repeated-measures analysis of variance was used for significance testing. RESULTS Adenosine had no effects on myocardial metabolism of oxygen, lactate and adenine nucleotides, postoperative enzyme release or haemodynamic performance. When compared with the antegrade groups, the retrograde groups showed higher myocardial oxygen uptake (17.3 ± 11.4 versus 2.5 ± 3.6 ml l(-1) at 60 min of aortic occlusion, P < 0.001) and lactate accumulation (43.1 ± 20.7 versus 36.3 ± 23.0 µmol g(-1) at 60 min of aortic occlusion, P = 0.052) in the myocardium during aortic occlusion, and lower postoperative left ventricular stroke work index (27.2 ± 8.4 versus 30.1 ± 7.9 g m m(-2), P = 0.034). CONCLUSIONS Adenosine 400 μmol l(-1) in cold blood cardioplegia showed no cardioprotective effects on the parameters studied. Myocardial ischaemia was more pronounced in patients receiving retrograde cardioplegia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108937      PMCID: PMC3420270          DOI: 10.1093/icvts/ivr027

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  22 in total

1.  Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery.

Authors:  R M Mentzer; P S Rahko; V Molina-Viamonte; C C Canver; P S Chopra; R B Love; T D Cook; J O Hegge; R D Lasley
Journal:  Am J Cardiol       Date:  1997-06-19       Impact factor: 2.778

2.  Does retrograde administration of blood cardioplegia improve myocardial protection during first operation for coronary artery bypass grafting?

Authors:  M Carrier; L C Pelletier; N R Searle
Journal:  Ann Thorac Surg       Date:  1997-11       Impact factor: 4.330

3.  Adenosine myocardial protection: preliminary results of a phase II clinical trial.

Authors:  R M Mentzer; V Birjiniuk; S Khuri; J E Lowe; P S Rahko; R D Weisel; H A Wellons; M L Barker; R D Lasley
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

4.  Optimal myocardial preconditioning in humans.

Authors:  G Cohen; T Shirai; R D Weisel; V Rao; F Merante; L C Tumiati; M K Mohabeer; M A Borger; R K Li; D A Mickle
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

5.  Adenosine's effect on myocardial functional recovery: substrate or signal?

Authors:  S F Bolling; K F Childs; X H Ning
Journal:  J Surg Res       Date:  1994-11       Impact factor: 2.192

6.  Which techniques of cardioplegia prevent ischemia?

Authors:  T M Yau; J S Ikonomidis; R D Weisel; D A Mickle; N Hayashida; J Ivanov; S Carson; M K Mohabeer; L C Tumiati
Journal:  Ann Thorac Surg       Date:  1993-11       Impact factor: 4.330

7.  Phase 2 studies of adenosine cardioplegia.

Authors:  G Cohen; R Feder-Elituv; J Iazetta; P Bunting; H Mallidi; J Bozinovski; C Deemar; G T Christakis; E A Cohen; B I Wong; R D McLean; M Myers; C D Morgan; C D Mazer; T S Smith; B S Goldman; C D Naylor; S E Fremes
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

8.  Pretreatment of human myocardium with adenosine during open heart surgery.

Authors:  H T Lee; R J LaFaro; G E Reed
Journal:  J Card Surg       Date:  1995-11       Impact factor: 1.620

9.  Postconditioning the human heart with adenosine in heart valve replacement surgery.

Authors:  Zhen-Xiao Jin; Jing-Jun Zhou; Mei Xin; Dao-Rong Peng; Xi-Ming Wang; Sheng-Hui Bi; Xu-Feng Wei; Ding-Hua Yi
Journal:  Ann Thorac Surg       Date:  2007-06       Impact factor: 4.330

10.  Myocardial protection during antegrade versus retrograde cardioplegia.

Authors:  P K Kaukoranta; M V Lepojärvi; K T Kiviluoma; K V Ylitalo; K J Peuhkurinen
Journal:  Ann Thorac Surg       Date:  1998-09       Impact factor: 4.330

View more
  3 in total

1.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

Review 2.  Hyperkalemic cardioplegia for adult and pediatric surgery: end of an era?

Authors:  Geoffrey P Dobson; Giuseppe Faggian; Francesco Onorati; Jakob Vinten-Johansen
Journal:  Front Physiol       Date:  2013-08-28       Impact factor: 4.566

3.  Temperature-Related Effects of Myocardial Protection Strategies in Swine Hearts after Prolonged Warm Ischemia.

Authors:  Anna Maria Tolomeo; Assunta Fabozzo; Ricardo Malvicini; Giada De Lazzari; Paola Bisaccia; Gianluca Gaburro; Diletta Arcidiacono; Denni Notarangelo; Federico Caicci; Fabio Zanella; Massimo Marchesan; Gustavo Yannarelli; Gianfranco Santovito; Maurizio Muraca; Gino Gerosa
Journal:  Antioxidants (Basel)       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.